イタシチニブの新興薬剤に関する洞察と市場予測：2032年

イタシチニブ（別名INCB-039110）は、経口で生物学的に利用可能なヤヌス関連キナーゼ1（JAK1）の阻害剤であり、抗悪性腫瘍作用および免疫調節作用が期待されます。経口投与により、イタシチニブはJAK-1を選択的に阻害し、それによってシグナル変換・転写活性化因子（STAT）タンパク質のリン酸化と、インターロイキン-23（IL-23）やインターロイキン-6（IL-6）を含むその他のサイトカインによって誘導される炎症性因子の産生を抑制します。JAK-STAT経路は多くのサイトカインや成長因子のシグナル伝達において重要な役割を果たしており、細胞増殖、成長、造血、免疫反応に関与しています。JAKキナーゼは炎症性疾患、骨髄増殖性疾患、様々な悪性腫瘍において発現が上昇する可能性があります。

今後数年間で、閉塞性細気管支炎症候群の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、イタシチニブの優位性に影響を与える可能性のある機会を模索しています。閉塞性細気管支炎症候群に対する他の新興製品は、イタシチニブに対して厳しい市場競合をもたらすと予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるイタシチニブ市場について調査し、市場の概要とともに、2031年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 閉塞性細気管支炎症候群に対するイタシチニブの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 製品概要

第3章 競合情勢（後期段階の新興治療法）

第4章 イタシチニブ市場評価

• 閉塞性細気管支炎症候群に対するイタシチニブの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における閉塞性細気管支炎症候群に対するイタシチニブの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: Itacitinib, Clinical Trial Description, 2023
• Table 2: Itacitinib, General Description
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: Itacitinib Market Size in the 7MM, in USD million (2019-2032)
• Table 5: Itacitinib Market Size in the US, in USD million (2019-2032)
• Table 6: Itacitinib Market Size in Germany, in USD million (2019-2032)
• Table 7: Itacitinib Market Size in France, in USD million (2019-2032)
• Table 8: Itacitinib Market Size in Italy, in USD million (2019-2032)
• Table 9: Itacitinib Market Size in Spain, in USD million (2019-2032)
• Table 10: Itacitinib Market Size in the UK, in USD million (2019-2032)
• Table 11: Itacitinib Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Itacitinib Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Itacitinib Market Size in the United States, USD million (2019-2032)
• Figure 3: Itacitinib Market Size in Germany, USD million (2019-2032)
• Figure 4: Itacitinib Market Size in France, USD million (2019-2032)
• Figure 5: Itacitinib Market Size in Italy, USD million (2019-2032)
• Figure 6: Itacitinib Market Size in Spain, USD million (2019-2032)
• Figure 7: Itacitinib Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Itacitinib Market Size in Japan, USD million (2019-2032)

“"Itacitinib Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about itacitinib for Bronchiolitis Obliterans Syndrome (BOS) in the seven major markets. A detailed picture of the itacitinib for bronchiolitis obliterans syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the itacitinib for bronchiolitis obliterans syndrome. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the itacitinib market forecast analysis for bronchiolitis obliterans syndrome in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in bronchiolitis obliterans syndrome.

Drug Summary:

Itacitinib (also known as INCB-039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of pro-inflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the itacitinib description, mechanism of action, dosage and administration, research and development activities in bronchiolitis obliterans syndrome.
• Elaborated details on itacitinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the itacitinib research and development activities in bronchiolitis obliterans syndrome across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around itacitinib.
• The report contains forecasted sales of itacitinib for bronchiolitis obliterans syndrome till 2032.
• Comprehensive coverage of the late-stage emerging therapies for bronchiolitis obliterans syndrome.
• The report also features the SWOT analysis with analyst views for itacitinib in bronchiolitis obliterans syndrome.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Itacitinib Analytical Perspective by DelveInsight

In-depth Itacitinib Market Assessment

This report provides a detailed market assessment of itacitinib for bronchiolitis obliterans syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2031 to 2032.

Itacitinib Clinical Assessment

The report provides the clinical trials information of itacitinib for bronchiolitis obliterans syndrome covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for bronchiolitis obliterans syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence itacitinib dominance.
• Other emerging products for bronchiolitis obliterans syndrome are expected to give tough market competition to itacitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of itacitinib in bronchiolitis obliterans syndrome.
• Our in-depth analysis of the forecasted sales data of itacitinib from 2031 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the itacitinib in bronchiolitis obliterans syndrome.

Key Questions:

• What is the product type, route of administration and mechanism of action of itacitinib?
• What is the clinical trial status of the study related to itacitinib in bronchiolitis obliterans syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the itacitinib development?
• What are the key designations that have been granted to itacitinib for bronchiolitis obliterans syndrome?
• What is the forecasted market scenario of itacitinib for bronchiolitis obliterans syndrome?
• What are the forecasted sales of itacitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to itacitinib for bronchiolitis obliterans syndrome?
• Which are the late-stage emerging therapies under development for the treatment of bronchiolitis obliterans syndrome?

Table of Contents

1. Report Introduction

2. Itacitinib Overview in Bronchiolitis Obliterans Syndrome

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. Itacitinib Market Assessment

• 4.1. Market Outlook of Itacitinib in Bronchiolitis Obliterans Syndrome
• 4.2. 7MM Analysis
  • 4.2.1. Market Size of Itacitinib in the 7MM for Bronchiolitis Obliterans Syndrome
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market Size of Itacitinib in the United States for Bronchiolitis Obliterans Syndrome
  • 4.3.2. Market Size of Itacitinib in Germany for Bronchiolitis Obliterans Syndrome
  • 4.3.3. Market Size of Itacitinib in France for Bronchiolitis Obliterans Syndrome
  • 4.3.4. Market Size of Itacitinib in Italy for Bronchiolitis Obliterans Syndrome
  • 4.3.5. Market Size of Itacitinib in Spain for Bronchiolitis Obliterans Syndrome
  • 4.3.6. Market Size of Itacitinib in the United Kingdom for Bronchiolitis Obliterans Syndrome
  • 4.3.7. Market Size of Itacitinib in Japan for Bronchiolitis Obliterans Syndrome

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options